COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review.
Rheumatol Int
; 41(4): 811-817, 2021 04.
Article
in English
| MEDLINE | ID: covidwho-1092075
ABSTRACT
Coronavirus disease 2019 (COVID-19) refers to the clinical picture of an important and severe infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Considering the current knowledge on the pathophysiology and clinical manifestations of COVID-19, it is safe to state that both COVID-19 and inflammatory rheumatic disorders cause a cytokine storm and merit treatment with anti-rheumatic drugs. Three patients, who were on regular follow-up due to the diagnosis of familial Mediterranean fever (FMF), contracted COVID-19 infection; and their pre-clinical and post-clinical data as well as laboratory, prognosis and treatment data were investigated. Effects of colchicine in FMF patients who contracted COVID-19 infection were presented in this study. All the cases recovered from COVID-19 without complications. The present study suggests that colchicine can positively affect the prognosis of COVID-19 in FMF patients; therefore, experience of rheumatologists in the use of anti-inflammatory drugs can be highly instrumental in management of COVID-19 patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Familial Mediterranean Fever
/
Colchicine
/
SARS-CoV-2
/
COVID-19 Drug Treatment
Type of study:
Case report
/
Cohort study
/
Experimental Studies
/
Prognostic study
Topics:
Variants
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Rheumatol Int
Year:
2021
Document Type:
Article
Affiliation country:
S00296-021-04809-3
Similar
MEDLINE
...
LILACS
LIS